Attachment A - BPA Price List - Diagnostic Reference Lab Services.xlsx
XLSX spreadsheet 40 KB Posted
- Attached to
- Diagnostic Reference Laboratory Testing
- Solicitation number
- ACQ-IHS-2026-U-0088
About this file
This is a Blanket Purchase Agreement (BPA) price list for diagnostic reference laboratory services provided by Neo-Genomics for the Indian Health Service (IHS) Pathology Department. The BPA covers a base year plus four option years and includes 249 line items encompassing flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), anatomic pathology, molecular pathology testing, and specialized diagnostic profiles branded as NeoTYPE and NeoLAB services.
The price list itemizes individual CPT codes and bundled testing panels across multiple service categories. Services include 10-color flow cytometry analysis with various marker configurations; cytogenetics chromosome analysis with setup, cell analysis, and interpretation; FISH procedures in both manual and automated formats for single and multiplex probe staining; anatomic pathology services such as blood smear interpretation, bone marrow analysis, surgical pathology, special stains, and immunohistochemistry (IHC) with qualitative and quantitative assessments; and comprehensive molecular pathology testing for mutations in genes such as ABL1, BCR-ABL1, BRAF, CALR, EGFR, FLT3, JAK2, and TP53. Advanced offerings include tumor-specific diagnostic profiles for hematologic malignancies (AML, ALL, CLL, lymphoma, MDS) and solid tumors (breast, lung, colorectal, gastric, ovarian, pancreatic, and others), as well as liquid biopsy services. The price list also includes specimen hold options for cytogenetics culture, FISH harvest, and nucleic acid extraction. However, all unit costs and annual costs are listed as "$-0," indicating this is a template or blank price list awaiting actual pricing data to be completed by the contractor during contract negotiations.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| ACQ-IHS-2026-U-0088.pdf | ||
| SOW - Diagnostic Reference Laboratory Testing Services.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
NEO-GENOMICS
| Base Year | Option Year 1 | Option Year 2 | Option Year 3 | Option Year 4 | ||||||||||||||
| No. | CPT CODE | DESCRIPTION | U/M | A/U | UNIT COST | ANNUAL COST | A/U | UNIT COST | ANNUAL COST | A/U | UNIT COST | ANNUAL COST | A/U | UNIT COST | ANNUAL COST | A/U | UNIT COST | ANNUAL COST |
| 1 | 88184 | 10 Color Flow Cytometry - General Pricing - Technical Component - 1st marker | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 2 | 88185 | 10 Color Flow Cytometry - General Pricing - Additional Markers | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 3 | 88187 | 10 Color Flow Cytometry - General Pricing - Flow interpretation (2-8 Markers) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 4 | 88188 | 10 Color Flow Cytometry - General Pricing - Flow Interpretation (9-15 Markers) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 5 | 88189 | 10 Color Flow Cytometry - General Pricing - Flow Interpretation (16+ markers) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 6 | 88184, 88185x7 | 10 Color Flow Cytometry - Special Pricing - Flow Profile PNH Tech (8) | 1/EA | 5 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | 8 | $ - 0 | |||||
| 7 | 88184, 88185x7, 88188 | 10 Color Flow Cytometry - Special Pricing - Flow Profile PNH Global (8) | 1/EA | 5 | $ - 0 | 9 | $ - 0 | 9 | $ - 0 | 9 | $ - 0 | 9 | $ - 0 | |||||
| 8 | 88182 | 10 Color Flow Cytometry - Special Pricing - Flow Profile DNA Global | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 9 | 88184, 88185x19, 88189 | 10 Color Flow Cytometry - Special Pricing - AML RD Flow Panel | 1/EA | 10 | $ - 0 | 21 | $ - 0 | 21 | $ - 0 | 21 | $ - 0 | 21 | $ - 0 | |||||
| 10 | 88184, 88185x30 | Extended Leukemia/Lymphoma Panel (Tech) | 1/EA | 10 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | 31 | $ - 0 | |||||
| 11 | 88184, 88185x30, 88189 | Extended Leukemia/Lymphoma Panel (Global) | 1/EA | 10 | $ - 0 | 32 | $ - 0 | 32 | $ - 0 | 32 | $ - 0 | 32 | $ - 0 | |||||
| 12 | 88237, 88230, 88239 | Cytogenetics - Chromosome Analysis (Set up) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 13 | 88261, 88262, 88264 | Cytogenetics - Chromosome Analysis (Cell Analysis) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 14 | 88291 | Cytogenetics - Chromosome Analysis Interpretation | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 15 | 88280 | Cytogenetics - Additional Karyotypes | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 16 | 88285 | Cytogenetics - Additional Cells | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 17 | 88237, 88239 | Cytogenetics - Additional Culture | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 18 | 88230, 88237, 88239 | Cytogenetics - No Growth | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 19 | 88368TC | FISH Manual - Tech only (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 20 | 882368PC | FISH Manual - Interp (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 21 | 88368 | FISH Manual - Global (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 22 | 88369TC | FISH Manual - Tech only (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 23 | 88369PC | FISH Manual - Interp (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 24 | 88369 | FISH Manual - Global (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 25 | 88377TC | FISH Manual - Tech only (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 26 | 88377PC | FISH Manual - Interp (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 27 | 88377 | FISH Manual - Global (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 28 | 88367TC | FISH Auto - Tech (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 29 | 88367PC | FISH Auto - Interp (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 30 | 88367 | FISH Auto - Global (Initial Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 31 | 88373TC | FISH Auto - Tech (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 32 | 88373PC | FISH Auto - Interp (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 33 | 88373 | FISH Auto - Global (Addn'l Single Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 34 | 88374TC | FISH Auto - Tech (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 35 | 88374PC | FISH Auto - Interp (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 36 | 88374 | FISH Auto - Global (Each Multiplex Probe Staining Procedure) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 37 | 88120TC | Bladder Cancer FISH Tech (4 probes) - Manual Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 38 | 88120PC | Bladder Cancer FISH Interp (4 probes) - Manual Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 39 | 88120 | Bladder Cancer FISH Global (4 probes) - Manual Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 40 | 88121TC | Bladder Cancer FISH Tech (4 probes) - Auto Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 41 | 88121PC | Bladder Cancer FISH Interp (4 probes) - Auto Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 42 | 88121 | Bladder Cancer FISH Global (4 probes) - Auto Read | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 43 | 85060 | Anatomic Pathology - Blood Smear Interp | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 44 | 85097 | Anatomic Pathology - Bone Marrow Interp | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 45 | 88305 | Anatomic Pathology - Surgical Pathology | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 46 | 88305TC | Anatomic Pathology - Surgical pathology Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 47 | 88311 | Anatomic Pathology - Decalcification | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 48 | 88311TC | Anatomic Pathology - Decalcification Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 49 | 88312 | Anatomic Pathology - Special Stain | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 50 | 88312TC | Anatomic Pathology - Special Stain Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 51 | 88313 | Anatomic Pathology - Tissue Special Stain | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 52 | 88313TC | Anatomic Pathology - Tissue Special Stain Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 53 | 88319 | Anatomic Pathology - CytoChemistry | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 54 | 88319TC | Anatomic Pathology - CytoChemistry Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 55 | 88321 | Anatomic Pathology - Consult | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 56 | 88323 | Anatomic Pathology - Professional Consult | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 57 | 88323TC | Anatomic Pathology - Professional Consult Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 58 | 88325 | Anatomic Pathology - Comprehensive Consult | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 59 | 88341 | Anatomic Pathology - IHC Qualitative; addn'l stain procedure | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 60 | 88341TC | Anatomic Pathology - IHC Qualitative; addn'l stain procedure Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 61 | 88342 | Anatomic Pathology - IHC Qualitative; per specimen; initial single antibody stain | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 62 | 88342TC | Anatomic Pathology - IHC Qualitative; per specimen; initial single antibody stain Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 63 | 88344 | Anatomic Pathology - IHC Qualitative; per specimen; multiplex antibody stain | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 64 | 88344TC | Anatomic Pathology - IHC Qualitative; per specimen; multiplex antibody stain Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 65 | 88360 | Anatomic Pathology - PDL1 (KEYTRUDA, OPDIVO, TECENTRIQ), Glo | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 66 | 88360TC | Anatomic Pathology - PDL1 (KEYTRUDA, OPDIVO, TECENTRIQ), Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 67 | 88360 | Anatomic Pathology - IHC Quantitative | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 68 | 88360TC | Anatomic Pathology - IHC Quantitative Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 69 | 88360 | Anatomic Pathology - FOLR1, GLO | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 70 | 88360TC | Anatomic Pathology - FOLR1, Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 71 | 88360 | Claudin 18 FDA (VYLOY) for Gastric/GEJ Adenocardnoma, Glo | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 72 | 88360TC | Claudin 18 FDA (VYLOY) for Gastric/GEJ Adenocardnoma, Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 73 | 88360 | c-MET CDx for NSCLC, Glo | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 74 | 88360TC | c-MET CDx for NSCLC, Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 75 | 88361 | Anatomic Pathology - IHC Morphometric Analysis, Computer assist, Glo | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 76 | 88361TC | Anatomic Pathology - IHC Morphometric Analysis, Computer assist, Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 77 | 88365 / 88364 | Anatomic Pathology - IHC by ISH | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 78 | 88365TC / 88364TC | Anatomic Pathology - IHC by ISH TC | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 79 | 88365 / 88364 | Anatomic Pathology - HPV ISH | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 80 | 88365TC / 88364TC | Anatomic Pathology - HPV ISH, Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 81 | 81170 | Molecular Pathology Testing - ABL1 Kinase Domain Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 82 | 81479 | Molecular Pathology Testing - BCR-ABL1 Standard p210, p190 | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 83 | 81206 | Molecular Pathology Testing - Quantitative BCR/ABL, t(9;22) Major (p210) for CML | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 84 | 81207 | Molecular Pathology Testing - Quantitative BCR/ABL, t(9;22) Minor (p190) for ALL | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 85 | 81208 | Molecular Pathology Testing - BCR-ABL1 Non-Standard p230 | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 86 | 81479 | Molecular Pathology Testing - B-Cell Gene Rearrangement | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 87 | 81261 | B-Cell Gene Rearrangement - IGH | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 88 | 81264 | B-Cell Gene Rearrangement - IGK | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 89 | 81340 | Molecular Pathology Testing - T-Cell Receptor Beta Gene Rearrangement | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 90 | 81342 | Molecular Pathology Testing - T-Cell Receptor Gamma Gene Rearrangement | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 91 | 81479 | Molecular Pathology Testing - B&T-Cell gene Rearrangement | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 92 | 81261 | Molecular Pathology Testing - B-Cell Gene Rearrangement - IGH | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 93 | 81264 | Molecular Pathology Testing - B-Cell Gene Rearrangement - IGK | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 94 | 81342 | Molecular Pathology Testing - T-Cell Receptor Gamma Gene Rearrangement | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 95 | 81210 | Molecular Pathology Testing - BRAF Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 96 | 81479 | Molecular Pathology Testing - BRCA1/2 Mutation Analysis for Tumors | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 97 | 81479 | Molecular Pathology Testing - BTK Inhibitor Acquired Resistance Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 98 | 81219 | Molecular Pathology Testing - CALR Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 99 | 81218 | Molecular Pathology Testing - CEBPA Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 100 | 81272 | Molecular Pathology Testing - KIT (c-KIT) Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 101 | 81479 | Molecular Pathology Testing - CSF3R Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 102 | 81479 | Molecular Pathology Testing - CXCR4 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 103 | 81235 | Molecular Pathology Testing - EGFR Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 104 | 81479 | Molecular Pathology Testing - FLT3 (ITD & TKD) Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 105 | 81245 | Molecular Pathology Testing - FLT3 (incl D385) Mutation Analysis (Bi-directional Seq & Fragment Length) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 106 | 81246 | Molecular Pathology Testing - FLT3 (incl D385) Mutation Analysis (Bi-directional Seq & Fragment Length) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 107 | 87624 | Molecular Pathology Testing - FLT3 by PCR | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 108 | 87624 | Molecular Pathology Testing - HPV DNA Tissue Testing | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 109 | 81479 | Molecular Pathology Testing - IDH1 and IDH2 Mutations Analysis by PCR | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 110 | 81263 | Molecular Pathology Testing - IgH Clonality by NGS | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 111 | 81263 | Molecular Pathology Testing - IgVH Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 112 | 81401 | Molecular Pathology Testing - Inv(16), CBFB-MYH11 Translocation | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 113 | 81270 | Molecular Pathology Testing - JAK2 V617F Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 114 | 81279 | Molecular Pathology Testing - JAK2 EXON 12-13 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 115 | 81270, 81279 | Molecular Pathology Testing - JAK2 V617F with reflex to EXON 12-13 Mutation Analysis | 1/EA | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | 2 | $ - 0 | |||||
| 116 | 81479 | Molecular Pathology Testing - KRAS Mutation Analysis by PCR | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 117 | 81479 | Molecular Pathology Testing - MET Exon 14 Deletion Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 118 | 81287 | Molecular Pathology Testing - MGMT Promoter Methylation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 119 | 81301 | Molecular Pathology Testing - MicroSatellite Instability Analysis (MSI) by PCR | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 120 | 81288 | Molecular Pathology Testing - MLH1 Promoter Methylation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 121 | 81339 | Molecular Pathology Testing - MPL Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 122 | Molecular Pathology Testing - MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, & MPL | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 123 | 81270 | Molecular Pathology Testing - JAK2 V617F Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 124 | 81279 | Molecular Pathology Testing - JAK2 EXON 12-13 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 125 | 81219 | Molecular Pathology Testing - CALR Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 126 | 81339 | Molecular Pathology Testing - MPL Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 127 | 81305 | Molecular Pathology Testing - MYD88 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 128 | 81194 | Molecular Pathology Testing - NTRK NGS Fusion Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 129 | 81479 | Molecular Pathology Testing - NTRK & RET NGS Fusion Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 130 | 81479 | Molecular Pathology Testing - NOTCH1 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 131 | 81310 | Molecular Pathology Testing - NPM1 MRD Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 132 | 81310 | Molecular Pathology Testing - NPM1 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 133 | 81311 | Molecular Pathology Testing - NRAS Mutation Analysis by PCR | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 134 | 81314 | Molecular Pathology Testing - PDGFRa Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 135 | 81315 | Molecular Pathology Testing - PML-RARA Translocation, t(15;17) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 136 | 81479 | Molecular Pathology Testing - Rapid AML Therapeutic Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 137 | 81479 | Molecular Pathology Testing - RAS/RAF Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 138 | 81401 | Molecular Pathology Testing - RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 139 | 81479 | Molecular Pathology Testing - Sarcoma Comprehensive NGS Fusion Panel | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 140 | 81149 | Molecular Pathology Testing - Targeted Solid Tumor NGS Fusion Panel | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 141 | 81345 | Molecular Pathology Testing - TERT Promoter Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 142 | 81352 | Molecular Pathology Testing - TP53 Mutation Analysis | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 143 | 81479 | Molecular Pathology Testing - UNIVERSAL Solid Tumor NGS Fusion Panel | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 144 | 81479 | NeoTYPE - AITL/ Peripheral T-Cell Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 145 | 81450 | NeoTYPE ALL Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 146 | 81450 | NeoTYPE ALL Profile - NEO AML Express | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 147 | 81450 | NeoTYPE AML Prognostic Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 148 | 81479 | NeoTYPE CLL Prognostic Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 149 | 81479 | Neo Comprehensive - Heme Cancers | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 150 | 81450 | NeoTYPE Follicular Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 151 | 81479 | NeoTYPE Lymphois Disorders Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 152 | 81450 | NeoTYPE Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 153 | 81450 | NeoTYPE MDS/ CMML Proflie | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 154 | 81479 | Neo Comprehensive Myeloid Disorders | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 155 | 81479 | NeoTYPE Breast Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 156 | 81479 | NeoTYPE Cervical Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 157 | 81445 | NeoTYPE Cholangiocarcinoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 158 | 81479 | NeoTYPE Colorectal Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 159 | 81479 | NeoTYPE DNA & RNA - Brain | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 160 | 81479 | NeoTYPE DNA & RNA - Lung | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 161 | 81479 | NeoTYPE Endometrial Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 162 | 81479 | NeoTYPE Esophageal Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 163 | 81479 | NeoTYPE Gastric Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 164 | 81479 | NeoTYPE GI Predictive Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 165 | 81479 | NeoTYPE GIST/Soft Tissue Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 166 | 81479 | NeoTYPE Head & Neck Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 167 | 81445 | NeoTYPE HRR Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 168 | 81479 | NeoTYPE Liver/ Biliary Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 169 | 81479 | NeoTYPE Lung Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 170 | 81479 | NeoTYPE Melanoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 171 | 81479 | NeoTYPE Other Solid Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 172 | 81479 | NeoTYPE Ovarian Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 173 | 81479 | NeoTYPE Pancreas Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 174 | 81479 | NeoTYPE Precision Profile for Solid Tumor | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 175 | 81479 | NeoTYPE Thyroid Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 176 | 81479 | PanTracer Tissue | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 177 | 81478 | PanTracer Tissue + HRD | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 178 | 81479 | NeoTYPE AITL/ Peripheral T-Cell Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 179 | 81450, 88374x2 | NeoTYPE ALL Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 180 | NEO AML Express | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 181 | 81450 | NeoTYPE AML Prognostic Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 182 | 81479, 88374x4 | NeoTYPE CLL Prognostic Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 183 | 81479 | Neo Comprehensive - Heme Cancers | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 184 | 81450, 88374x3 | NeoTYPE Follicular Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 185 | 81479 | NeoTYPE Lymphoid Disorders Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 186 | 81450, 88374x2 | NeoTYPE Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 187 | 81450 | NeoTYPE MDS/ CMML Proflie | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 188 | 81479 | Neo Comprehensive - Myeloid Disorders | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 189 | 81479, 88377x2, 88360, 88342 | NeoTYPE Breast Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 190 | 81479, 88377x2, 88360, 88342 | NeoTYPE Cervical Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 191 | 81445, 88374, 88360 | NeoTYPE Cholangiocarcinoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 192 | 81479, 88377x3, 88360X2, 88342 | NeoTYPE Colorectal Tumor Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 193 | 81479, 88377x8, 88360 | NeoTYPE DNA & RNA - Brain | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 194 | 81479, 88360 | NeoTYPE DNA & RNA - Lung | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 195 | 81479, 88377x2, 88360x2, 88342 | NeoTYPE Endometrial Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 196 | 81479, 88377x2, 88360, 88342 | NeoTYPE Esophageal Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 197 | 81479, 88377x2, 88360, 88361x4, 88342 | NeoTYPE Gastric Tumor Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 198 | 81479, 88377x2, 88360, 88342 | NeoTYPE Gastric Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 199 | 81479, 88374, 88360X2, 88342 | NeoTYPE GI Predictive Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 200 | 81479, 88377x2, 88360 | NeoTYPE GIST/Soft Tissue Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 201 | 81479, 88377x3, 88360, 88342, 88365 | NeoTYPE Head & Neck Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 202 | 81445, 88360 | NeoTYPE HRR Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 203 | 81479, 88377X3, 88360, 88342 | NeoTYPE Liver/ Biliary Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 204 | 81479, 88374, 88377x5, 88360x2, 88342 | NeoTYPE Lung Tumor Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 205 | 81479, 88377, 88360, 88342 | NeoTYPE Melanoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 206 | 81479, 88377x2, 88360, 88342 | NeoTYPE Other Solid Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 207 | 81479, 88374, 88377x5, 88360x2, 88342 | NeoTYPE Ovarian Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 208 | 81479, 88377x3, 88360x2, 88342 | NeoTYPE Pancreas Tumor Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 209 | 81479, 88360, 88342 | NeoTYPE Precision Profile for Solid Tumor | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 210 | 81479, 88377x3, 88360x2, 88342 | NeoTYPE Thyroid Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 211 | 81479 | PanTracer Tissue | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 212 | 81479 | PanTracer Tissue + HRD | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 213 | 81450, 88374TCx2 | NeoTYPE ALL Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 214 | 81479, 88374TCx4 | NeoTYPE CLL Prognostic Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 215 | 81450, 88374TCx3 | NeoTYPE Follicular Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 216 | 81450, 88374TCx2 | NeoTYPE Lymphoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 217 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Breast Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 218 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Cervical Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 219 | 81479, 88374TC, 88360TC | NeoTYPE Cholangiocarcinoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 220 | 81479, 88377TCx3, 88360TCx2, 88342TC | NeoTYPE Colorectal Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 221 | 81479, 88377TCx8, 88360TC | NeoTYPE DNA & RNA - Brain | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 222 | 81479, 8360TC | NeoTYPE DNA & RNA - Lung | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 223 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Endometrial Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 224 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Esophageal Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 225 | 81479, 88377TCx2, 88360TC, 88361TCx4, 88342TC | NeoTYPE Gastric Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 226 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Gastric Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 227 | 81479, 88374TC, 88360TCx2, 88342TC | NeoTYPE GI Predictive Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 228 | 81479, 88377TCx2, 88360TC | NeoTYPE GIST/Soft Tissue Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 229 | 81479, 88377TCx3, 88360TC, 88342TC, 88365TC | NeoTYPE Head & Neck Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 230 | 81445, 88360TC | NeoTYPE HRR Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 231 | 81479, 88377TCx3, 88360TC, 88342TC | NeoTYPE Liver/ Biliary Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 232 | 81479, 88374TC, 88377TCx5, 88360TCx2, 88342TC | NeoTYPE Lung Tumor Profile | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 233 | 81479, 88377TC, 88360TC, 88342TC | NeoTYPE Melanoma Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 234 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Other Solid Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 235 | 81479, 88374TC, 88377TCx5, 88360TCx2, 88342TC | NeoTYPE Ovarian Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 236 | 81479, 88377TCx3, 88360TCx2, 88342TC | NeoTYPE Pancreas Tumor Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 237 | 81479, 88360TC, 88342TC | NeoTYPE Precision Profile for Solid Tumor | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 238 | 81479, 88377TCx2, 88360TC, 88342TC | NeoTYPE Thyroid Profile | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 239 | 81479 | NeoLAB PANtRACER lbX | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 240 | 0388U | NeoLAB InVisionFirst Lung Liquid Biopsy | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 241 | 81445 | NeoLAB Solid Tumor Monitor - Liquid Biopsy | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 242 | 88381 | MicroDissection - Global | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 243 | 88381TC | MicroDissection - Tech | 1/EA | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | |||||
| 244 | Specimen Hold Options - Cytogenetics - Culture and Hold | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 245 | Specimen Hold Options - FISH - Direct Harvest and Hold for FISH | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 246 | Specimen Hold Options - Molecular Testing - Extract Nucleic Acid and Hold (DNA) | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 247 | Specimen Hold Options - Molecular Testing - Extract Nucleic Acid and Hold (RNA) | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 248 | Specimen Hold Options - Molecular Testing - Extract Nucleic Acid and Hold (TNA) | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| 249 | Specimen Hold Options - Molecular Testing - NEO PanTracer LBx Extract and Hold | 1/EA | 0 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | 1 | $ - 0 | ||||||
| $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 |
| Base Year: | |
| OY 1: | |
| OY 2: | |
| OY 3: | |
| OY 4: | |
| TOTAL: | $ - 0 |
File details come from the government source that posted it. Updated .